Premium Article

The [almost] unbelievable relationship between “big pharma” and gray-market peptides

Free Article

How much do symptomatic treatments for Alzheimer’s disease help?

Free Article

Myostatin inhibitors and the paradox of larger but weaker muscles

Guest Episode

Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients

Ep. #409 with Lloyd Klickstein, M.D., Ph.D.

AMA

Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

Ep. #408 (AMA #89)

Free Article

Can semaglutide slow aging?

Guest Episode

Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies

Ep. #407 with Michael Davidson, M.D.

Premium Article

GLP-1 medications beyond weight loss: how far could their benefits extend?

Guest Episode

Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies

Ep. #404 with Linus Abrams, M.D.

Podcast Episode

Peptides: separating scientific promise from marketing hype

Ep. #403

Free Article

Lithium and Alzheimer’s disease: what to weave of this LATTICE?

Guest Episode

The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape

Ep. #399 with Gayatri Devi, M.D.

Free Article

Metformin and cancer: active surveillance needed

AMA

GLP-1 RAs and muscle loss

Ep. #398 (AMA #86)

Guest Episode

Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health

Ep. #395 with Tom Dayspring, M.D.

Premium Article

Growth hormone for musculoskeletal system repair

AMA

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they’re working for you

Free Article

Updated cardiovascular guidelines—statin use in patients as young as 30

AMA

Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

Ep. #385 (AMA #82)

Podcast Episode

Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Ep. #384

Premium Article

GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease

Free Article

Metformin misses the mark?

Premium Article

Navigating the complex relationship between statins, GLP-1, and glycemic control

Guest Episode

Women’s health and performance: how training, nutrition, and hormones interact across life stages

Ep. #378 with Abbie Smith-Ryan, Ph.D.